Replies to post #332228 on Avid Bioservices Inc (CDMO)

[biopharm]

I disagree

Min Yue leaves Eli Lilly / US based Green Valley Pharmaceuticals for China based, parent company and approved PS Targeting drug approved for Alzheimer's now

Just as Eli Lilly / Omeros published the PS Targeting relevance Sept 10, 2019 ...knowing Min Yue leaves with IP asset material info

Targeting flipped PS has always been the target...just ask Lockheed Martin with their Targeting of flipped PS patent approved in Feb 2017 when Stafford arrived on scene


Patent Inventor

Byron W. Tietjen
Paul Declan Mountcastle
Svetlana Monakhova Bachmann

https://pubchem.ncbi.nlm.nih.gov/patent/US9572918

___

Don't worry.... ALL info has been forwarded and I know some don't like so we shall see how this plays out

INmune Bio low profile .... ties Xencor and Merck

Ties Raymond J Tesi ....ties SonosBio

Edgardo ( Ed) Baracchini - CBO at Xencor

Byron W. Tietjen - patent ties Lockheed Martin
___

SITC 2019 Oncologie CEO Laura Benjamin speaking this week on PS Targeting Biomarkers etc

I have never known of a shareholder for Avid CDMO that likes to hide the facts...but China changed it's laws and can approve drugs based on surrogate endpoints / Biomarkers discovered in US now

Time for everyone to wake up and ask why Ampersand is shelling out more CDMOs like Arranta on Thermofisher deals and remains QUIET on Avid CDMO